10-Q/A: Chain Bridge I Restates Q3, Faces Delisting & SPAC Deal Collapse

Chain Bridge I filed an amended quarterly report, restating financials due to accounting errors, revealing a material weakness in internal controls, and announcing the termination of its business combination with Phytanix Bio, leading to Nasdaq delisting.

Summary

• Chain Bridge I (CBRRF) filed an amended Quarterly Report (Form 10-Q/A) for the period ended September 30, 2024, to correct accounting errors.
• The company understated liabilities and expenses by $200,000 related to a third-party payment for legal services and overstated prepaid expenses by $97,500.
• These errors resulted in an overstatement of net income by $297,500 for the three and nine months ended September 30, 2024.
• Net income for the three months ended September 30, 2024, was restated from $623,976 to $326,476.
• Net loss for the nine months ended September 30, 2024, was restated from $(1,061,871) to $(1,359,371).
• Management concluded that disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting related to the review and reconciliation of liabilities and prepaid expenses.
• The previously announced Business Combination Agreement with Phytanix Bio, valued at $58 million, was mutually terminated on April 7, 2025.
• The company's securities were delisted from Nasdaq on November 19, 2024, due to failure to complete a business combination within 36 months, and now trade on OTCQB and Pink Open Market.
• As of September 30, 2024, the company had cash of $428,625 and a working capital deficit of $583,851, raising substantial doubt about its ability to continue as a going concern.
• The deadline to consummate a business combination has been extended to November 15, 2025, with a proposal to further extend to November 15, 2026, and remove the $5,000,001 net tangible assets limitation.

Sentiment

Score: 2

Explanation: The combination of a material financial restatement, identified material weakness in internal controls, Nasdaq delisting, and the termination of the primary business combination target paints a highly negative picture. The company faces significant operational and financial challenges, including substantial doubt about its ability to continue as a going concern.

Positives

• The company regained compliance with Nasdaq's 300 public holders rule on September 13, 2024, prior to the delisting for other reasons.
• Management is devoting significant effort and resources to remediate the identified material weakness in internal controls.
• Fulton AC and the Sponsor have made contributions to the Trust Account and agreed to reimburse dissolution expenses, providing some financial support.

Negatives

• Financial statements for Q3 2024 required restatement due to material accounting errors, leading to a significant reduction in reported net income and an increase in net loss.
• Management identified a material weakness in internal control over financial reporting, indicating inadequate review and reconciliation processes.
• Disclosure controls and procedures were deemed ineffective.
• The Business Combination Agreement with Phytanix Bio, a key strategic move, was mutually terminated.
• The company's securities were delisted from Nasdaq on November 19, 2024, due to failure to complete a business combination within the required timeframe, moving trading to less liquid OTC markets.
• The company has a working capital deficit of $583,851 as of September 30, 2024.
• The company's ability to continue as a going concern is in substantial doubt due to liquidity conditions and the mandatory liquidation date if a business combination is not completed.

Risks

• A material weakness in internal controls over financial reporting could lead to future misstatements and an inability to produce accurate financial statements.
• Failure to successfully remediate the material weakness could adversely affect the stock price and compliance with listing requirements (though already delisted from Nasdaq).
• The company's ability to continue as a going concern is in substantial doubt, potentially leading to liquidation if a business combination is not consummated by November 15, 2025 (or an extended date).
• Delisting from Nasdaq could materially adversely impact the ability to locate another target for an initial business combination and would likely cause liquidation if a new deal is not found.
• Warrants may expire worthless if the company fails to complete a business combination by the termination date and liquidates.
• Geopolitical events, adverse economic developments, inflation, and interest rates could negatively affect the company's financial position and search for a target company.

Future Outlook

The company expects to continue devoting significant effort and resources to remediate the material weakness in internal controls over financial reporting. The company has until November 15, 2025, to consummate an initial Business Combination, with a proposal to extend this to November 15, 2026. If a business combination is not completed by the termination date, the company must cease operations, redeem public shares, and liquidate. The delisting from Nasdaq is expected to materially adversely impact the ability to locate another target for an initial business combination and would likely cause liquidation if a new deal is not found. The surviving company (if a business combination occurs) will apply to list its securities on Nasdaq Capital Markets.

Management Comments

• Our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures... and concluded that our disclosure controls and procedures are not effective because of a material weakness in our internal control over financial reporting related to the adequate review and reconciliation of its liabilities and prepaid expenses.
• Management has devoted, and plans to continue to devote, significant effort and resources to the remediation and improvement of its internal controls over financial reporting.
• Management believes that the financial statements included in this Quarterly Report present fairly in all material respects our financial position, results of operations and cash flows for the period presented.
• The Company has determined that the liquidity condition and the date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Companys ability to continue as a going concern.
• We do not expect the delisting to impact our ability to consummate the previously disclosed business combination with Phtytanix Bio (the Phytanix Business Combination).

Industry Context

This filing highlights the inherent risks and challenges faced by Special Purpose Acquisition Companies (SPACs), particularly in meeting deadlines for business combinations and maintaining listing compliance. The delisting from Nasdaq and subsequent trading on OTC markets is a common outcome for SPACs that fail to complete a de-SPAC transaction within the regulatory timeframe, significantly reducing liquidity and investor interest. The termination of the business combination with Phytanix Bio underscores the difficulty in successfully executing these complex transactions, often due to market conditions, due diligence findings, or inability to meet closing conditions. The repeated extensions of the business combination deadline and ongoing capital contributions from the sponsor reflect the typical efforts SPACs undertake to stay afloat while searching for or attempting to close a deal.

Comparison to Industry Standards

• The restatement of financial statements and the identified material weakness in internal controls are below industry standards for financial reporting integrity and corporate governance. Public companies are expected to maintain effective internal controls to ensure accurate financial reporting.
• The delisting from Nasdaq is a significant negative event, as Nasdaq listing provides greater visibility, liquidity, and investor confidence compared to OTC markets. Most successful SPACs aim to maintain a national exchange listing post-combination.
• The termination of a definitive business combination agreement, especially after significant effort and multiple extensions, is a substantial setback and indicates a failure to meet a primary objective for a SPAC. Successful SPACs complete their initial business combination.
• The ongoing 'going concern' doubt is a red flag, indicating the company's precarious financial position, which is not uncommon for SPACs nearing their liquidation deadline without a definitive, viable business combination.

Management Changes

Corporate Governance

Related Party Transactions

• CBG and CB Co-Investment initially paid $25,000 for 8,625,000 Class B ordinary shares.
• CB Co-Investment's $1.15 million loan was irrevocably agreed to convert into 1,150,000 contingently issuable Private Placement Warrants upon business combination.
• CBG's $1.2 million Additional Convertible Note was terminated, with proceeds recognized as a capital contribution.
• Fulton AC's $1.5 million Fulton AC Note was exchanged for the Exchange Note, with $296,942 outstanding as of September 30, 2024.
• The company pays Fulton AC up to $30,000 per month for office space, administrative, and support services under the Fulton Services Agreement.
• RSU grants were made to directors Lewis Silberman (50,000), Paul Baron (50,000), and Oliver Wiener (50,000), contingent on business combination and incentive plan approval.
• Roger Lazarus's initial RSU grant (70,000) terminated upon resignation, but a new grant of 30,000 RSUs in the target company was agreed for advisory services.
• Fulton AC, CBG, CB Co-Investment, and current/former directors/officers agreed to vote Class B shares in favor of a business combination and waive redemption rights.
• Fulton AC agreed to indemnify the Trust Account for certain claims by third parties.
• Sponsor (Fulton AC) has made and committed to ongoing monthly contributions to the Trust Account to extend the company's life.

Stakeholder Impact

• Shareholders: Significant negative impact due to financial restatement, material weakness, Nasdaq delisting, and termination of the business combination. Public shareholders face reduced liquidity and potential loss of investment if liquidation occurs.
• Management: Faces increased scrutiny and workload due to remediation of internal control weaknesses and the ongoing search for a new business combination.
• Creditors: New debt instruments (Exchange Note, Bridge Financing Note, C/M Capital Master Fund LP Note) indicate ongoing financing needs and potential exposure if the company liquidates.
• Employees: Uncertainty regarding future employment given the 'going concern' doubt and the need to find a new business combination.

Next Steps

• Management plans to continue devoting significant effort and resources to remediate the material weakness in internal controls over financial reporting.
• The company needs to identify and consummate a new initial business combination by November 15, 2025 (or November 15, 2026, if the proposed amendment is approved).
• The company will apply to list its securities on Nasdaq Capital Markets upon consummation of a business combination.
• A shareholder meeting is scheduled for October 29, 2025, to vote on extending the business combination deadline to November 15, 2026, and removing the $5,000,001 net tangible assets limitation.
• The company needs to establish and authorize a new series of preferred shares by November 15, 2025, as per the terms of the Note to C/M Capital Master Fund LP.

Key Dates

Recommendation

The company faces severe challenges, including a material financial restatement, ineffective internal controls, and a Nasdaq delisting. The termination of its primary business combination target, Phytanix Bio, leaves it without a clear path forward and under significant pressure to find a new deal before its liquidation deadline. The 'going concern' doubt further highlights the high risk of capital loss. Given these compounding negative factors, a seasoned investor would likely recommend selling to minimize further exposure.

Keywords

SPAC, Chain Bridge I, CBRRF, 10-Q/A, Restatement, Financial Reporting, Internal Controls, Material Weakness, Nasdaq Delisting, Business Combination Termination, Phytanix Bio, Going Concern, Liquidity, Warrants, Fulton AC, SEC Filing